Pages that link to "Q41014982"
Jump to navigation
Jump to search
The following pages link to Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates (Q41014982):
Displaying 30 items.
- Improving the efficacy of antibody-based cancer therapies (Q28208361) (← links)
- Clinical immunotherapy for brain tumors (Q30784536) (← links)
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients (Q33400076) (← links)
- Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis (Q33696680) (← links)
- An overview of targeted alpha therapy (Q34238513) (← links)
- Advancements in cancer therapy with alpha-emitters: a review (Q34343330) (← links)
- Transcriptional response in normal mouse tissues after i.v. (211)At administration - response related to absorbed dose, dose rate, and time (Q35261291) (← links)
- Peptide-targeted radionuclide therapy for melanoma (Q35393994) (← links)
- Molecular targeted α-particle therapy for oncologic applications (Q35814989) (← links)
- Radioimmunotherapy of leukemia (Q35909305) (← links)
- Cancer radioimmunotherapy with alpha-emitting nuclides (Q36102652) (← links)
- Microdosimetric analysis of 211At in thyroid models for man, rat and mouse (Q36239833) (← links)
- Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation (Q36551498) (← links)
- Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation (Q36573009) (← links)
- A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker (Q39284797) (← links)
- A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry (Q40254341) (← links)
- In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen (Q40545805) (← links)
- The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study (Q40835671) (← links)
- Astatine-211-Labeled Biotin Conjugates Resistant to Biotinidase for Use in Pretargeted Radioimmunotherapy (Q54146952) (← links)
- Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate (Q55478572) (← links)
- Similarities and differences between free 211At and 125I− transport in porcine thyroid epithelial cells cultured in bicameral chambers (Q58354190) (← links)
- Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide (Q73195202) (← links)
- Advances in the use of monoclonal antibodies in cancer radiotherapy (Q73521309) (← links)
- Radioiodination and astatination of octreotide by conjugation labeling (Q74154270) (← links)
- Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals (Q74484257) (← links)
- Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi (Q74650700) (← links)
- Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate (Q77925172) (← links)
- Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up (Q78059037) (← links)
- Design and synthesis of 225Ac radioimmunopharmaceuticals (Q78446990) (← links)
- Alpha particles more promising than toxins? (Q83816172) (← links)